Coordinated Action on Host-Virus Interactions: Basic and Translational HIV Research (CA41)

Activities

• Scientific facilitation around priority topics, including the CA41 annual symposium and joint meetings with other Coordinated Actions (CA42, CA44)
• Organisation of international sessions and symposia to increase research visibility
• Encouragement of new collaborations and support of consortia around priority topics
• Activities to support young researchers: organisation of annual symposia dedicated to their work (Work in Progress– WIP); Dominique Dormont Thesis Prize, in association with the French Virology Society (SFV); facilitation of a young researchers’ network (ANRS MIE Young Basic research community network – AMYB)

This Coordinated Action has over 300 members.

Chair

Board members

ANRS MIE coordination

Workgroups

• CA44/41 WG – Immunotherapy Group (Pierre Delobel)
• CA44/41 WG – Mother and child Group (Valériane Leroy and Florence Buseyne)
• ThéGeVec WG – In 2025, a new working group on vectorology was launched : the ThéGeVec group, with the aim of structuring and accelerating research in Vectorology approaches designed to achieve more efficient and safer gene therapies.

1st symposium of the ThéGeVec working group

The ThéGéVec WG is pleased to announce its first symposium. This event will be held in person on 28 November 2025 at the Institut Pasteur.

The symposium will bring together leading experts and researchers to discuss the latest innovations in viral and non-viral vector technologies and their therapeutic applications. The focus will be on promoting collaboration within the scientific community and exploring new strategies to accelerate progress in this field. Research in all areas of vectorology and gene therapy is welcome.

• Abstract submission: 25 August – 15 September
• Registration: 15 July – 21 November

Genesis of the ThéGeVec working group

While France has been a pioneer in the first gene therapy trials, it now faces a concerning lag in innovation and translation in the field, despite its strong expertise and internationally recognized scientific excellence. Accordingly, existing skills seem to remain insufficiently connected, limiting their visibility—particularly among industrial stakeholders in the biomedical sector. After discussion of the AC41 with experts in Vectorology, the ThéGeVec working group was established.

A Vectorology coordination office with several experts in the field was then established, whose first mission was to define key objectives to advance the development of viral vector technologies for therapeutic use. The working group aligns with the strategic priorities of ANRS MIE, and regarding HIV, its defined priority on HIV Cure research. Importantly, the group aims to strengthen collaborations across the research community working on various infectious diseases in need of novel therapies. Finally, the group will actively interact with other coordinated actions of the ANRSMIE, with its Innovation Department as well as wi th already existing complementary national networks (ex. DYNAVIr, the French society of Cell and Gene therapy, and the French Society of nanomedicine).

The group will provide support for early-career scientists whenever possible, to help foster the new generation in the field.

ThéGéVec Coordination Team: Aurélie Albertini, Alexis Duvergé, Anne Galy, Yves Gaudin, Matteo Negroni (chair), Jean-Christophe Pagès, Chantal Pichon

Please note that the composition is not final and may evolve